Replies to post #398884 on Innovation Pharmaceuticals Inc (IPIX)

[StockJumper25]

Reminder of the focus of interest in Brilacidin by Baseila... Its only seem to be on the anti-infections and not what BRI can handle on the colon support side, it seems.
So, does that make an agreement on only suitable for an in-license agreement with no up-front cash transaction? Not sure in this case.

Background:
https://www.edisongroup.com/research/renewed-focus-on-anti-infectives/30855/
Search for Brilacidin

[Hazelhurst]

Good find. Brilacidin fits that mold. The only question is, can they come to agreement on fair/potential value? Also, have a feeling Merck is interested, with all that testing in Brazil, imo.

[djs7]

Rather see a global pharma. They are too small to get things moving expeditously. Also, a big pharma with money can run multiple trials of indication with varying dosages of the combination to improve chances for approval.

[farrell90]

Thanks for posting

2023:

BASILEA HALF-YEAR REPORT 202318
OUTLOOK:
BASILEA HALF-YEAR REPORT 202318
OUTLOOK pg 18

Upcoming milestones
H2 2023
In-licensing or acquisition of novel anti-infectives
to complement clinical pipeline
H1 2024
In-licensing or acquisition of novel anti-infectives
to complement clinical pipeline

Interesting they are making announcing corporate goal to acquire or license novel, complementary antiinfectives.

I do not know Basilea well enough to outline all the drugs they may be evaluating, but it is a sure bet Brilacidin is one of them.

JMHO, Farrell